ADU-1805 |
Catalog No.GC79352
One-Click Copy Product Info
|
ADU-1805 is a humanized monoclonal IgG2 antibody, a selective, pan-allelic anti- SIRPα antibody, with a K d value of 11.0 × 10 -9 M for hSIRPαV1.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
In Vivo, ADU-1805 (0.3-30 mg/kg; i.v.; single 15-minute infusion) is well tolerated in healthy cynomolgus monkeys, with stable hemoglobin levels and no observed toxicity over 59 days[1].
In Vitro, ADU-1805 binds to hSIRPαV1 with a Kd value of 11.0 × 10-9 M, and exhibits binding properties similar to those of the parental and chimeric hSIRPα.40A antibody variants[1]. ADU-1805 potently binds to primary monocytes and neutrophils, while exhibits extremely weak binding to lymphocytes[1]. ADU-1805 (0.67-66.7 nM; 2 h) promotes Rituximab -mediated phagocytosis of Raji Burkitt's lymphoma cells by peripheral blood-derived macrophages in a concentration-dependent manner[1]. ADU-1805 (0.067-66.7 nM; 2 h) enhances Rituximab-mediated trogocytosis of primary neutrophils against BJAB Burkitt's lymphoma cells in a concentration-dependent manner[1]. ADU-1805 does not bind to primary red blood cells or platelets, nor does it induce hemagglutination of red blood cells[1]. ADU-1805 (5 days) neither inhibits T cell activation nor reduces T cell counts in allogeneic mixed lymphocyte reactions[1]. ADU-1805 (100 μg/mL; 3 days) does not inhibit SEB-induced T cell activation and proliferation[1].
References:
[1]. Voets E, et al. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint. J Immunother Cancer. 2019;7(1):340. Published 2019 Dec 4.
| Cas No. | SDF | ||
| Formula | M.Wt | 145 | |
| Solubility | Storage | Store at -20°C | |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 6.8966 mL | 34.4828 mL | 68.9655 mL |
| 5 mM | 1.3793 mL | 6.8966 mL | 13.7931 mL |
| 10 mM | 689.7 μL | 3.4483 mL | 6.8966 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A liquid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)